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ABSTRACT 
Background: Migraine is an exceedingly common disorder that causes substantial pain, disability and societal burden. Unfortunately, 
conventional treatments are insufficient, inadequate, or associated with significant risks, such as overuse, abuse or addiction. The Unani system 
of Medicine has been treating migraine since centuries. Leech therapy (Irsale Alaq) has been employed successfully in severe persistent 
headache, mania and insomnia since decades.  
Aim: The purpose of our study was to evaluate the impact of post auricular leech therapy in migraine and to collect data to warrant further 
clinical trials. 
Methods: We conducted a case series on 7 patients who had failed conventional oral treatments for the migraine. After informed consent, post 
auricular leech therapy was done.  Patients were asked to keep detailed headache calendars, documenting the number of headache days, 
migraine days, the intensity of headaches/ migraines and analgesic usage. We compared these parameters before and after 2 months of therapy.  
Results: We observed a reduction in the number of headache & migraine days and amount of painkillers used without any adverse effects. (P≤ 
0.01) Improvement in quality of life was also observed. 
Discussion: We reviewed the literature related to the medicinal leeches (Hirudo medicinalis), used for the treatment in these cases. Leech saliva 
contains certain potent anesthetic, anti-inflammatory and vasodilator substances, suggesting plausible mechanisms of action in these cases. 
Conclusion: The preliminary findings indicate the safe and potential therapeutic role of leech therapy. So further trials should be carried out to 
explore the therapeutic potential of this therapy in chronic migraine. 
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Chronic migraine is a distinct and relatively recently defined 
sub-type of Chronic Daily Headache (CDH). Chronic Migraine 
(CM) is defined by the International Headache Society 
(ICHD-2R) as “a debilitating condition where patients suffer 
headaches for 15 days or more per month, with migraine on 
at least 8 of those days, 1 occurring in a patient with a 
lifetime history of at least five prior migraine attacks not 
attributed to another causative disorder and no medication 
overuse. 2 In real terms, this means that a person who is 
affected by CM has a headache or migraine for more than 
half the days in the month. Episodic migraine (EM) is the 
other sub-type of CDH, which is defined as less than 15 
headache days per month. 
Migraine is part of most disabling of neurological disorders. 
The World Health Organization (WHO) has identified 
migraine among the world’s top 19th leading causes of 
disability. 3 Estimates of migraine prevalence vary, due to 
non-uniform study methodology. There are no population–
based studies from India. Based on large epidemiologic 
studies worldwide, the prevalence of migraine was about 
18% of women and 6% of men. Migraine imposes an 
enormous health burden on individual headache sufferers 
and on society. It is a recurrent and often a lifelong illness 
characterized by attacks include features such as headache 
of moderate or severe intensity, nausea (the most 
characteristic), one-sided and/or pulsating quality, 
aggravated by routine physical activity with a duration of 
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hours to 2-3 days. Its prevalence peaks during the most 
productive years, between the ages of 25 and 55 years 
which leads to work loss and reduced productivity. 1, 4 CM 
population also had higher rates of cardiovascular and 
respiratory comorbidities, such as hypertension, high 
cholesterol, stroke, emphysema or chronic obstructive 
pulmonary disease, and asthma. 5 Therefore, WHO classified 
CM as more disabling than blindness, paraplegia, angina or 
rheumatoid arthritis.  
The migraine has been documented & described nearly in all 
classical text of Unani medicine as a disease entity 
“Shaqeeqa.” Shaqeeqa is an Arabic word, derived from the 
word “Shaq” which means a part or a side, as the headache is 
usually one sided. Hippocrates (460-375 BC) was the first to 
describe such constellation of symptoms that included aura, 
pain and vomiting as part of a singular disorder. 7, 8, 9 
Jalinoos/ Galen (131-201 AD) mentioned the disease 
“hemicrania” meaning “half of the head” to describe such 
headaches. Hemicrania translated from Greek to Latin 
became “hemicranium” and was transformed to “megrim” in 
old English and “migrain” in French. 8 
Leech therapy (Irsale Alaq) is one of a regimen under the 
regimenal therapy (Ilaj bit tadbeer) in Unani medicine.  10 
Medicinal leeches (Hirudo medicinalis) have been used in  
various clinical studies to provide relief in chronic pain 
conditions such as osteoarthritis 11-16, chronic pain syndrome 
17,  severe cancer pain 18 etc. including migraine. 19 So we 
performed the present case series to assess the impact of 
post-auricular leech therapy in CM cases. 
MATERIAL & METHODS  
Informed consent was drawn from the patients in their 
known languages. Study was approved by institutional ethics 
committee. Human data included in this case series was 
obtained in compliance with the Declaration of Helsinki as 
revised in 1983.  
Intervention 
Before leech therapy, patients were investigated with set of 
laboratory tests such as complete blood count, random blood 
sugar, clotting time (CT), bleeding time (BT), international 
normalized ration (INR) and detection test for HIV I & II, 
HBsAg and HCV to rule out any blood borne infectious 
disease, coagulation disorder, anemia, diabetes etc. which 
forbid leech application. After the fulfilling criteria, single 
medicinal leech (Hirudo medicinalis), was applied at post 
auricular region bilaterally every fifteen days for 2 months 
(at baseline, 15th day, 30th day and 45th day of enrollment).  
Procedure: Under hygienic condition, patient was allowed to 
lie down at prone position in the minor operation theatre. 
Post auricular region was cleaned with fresh water and 
draped. A small prick was given with a sterile needle at post 
auricular region at the level of auricular tubercle. Let the 
small amount of blood to oozed out so that the leech could 
get attached easily. 1 medicinal leech was applied.  
After 30 min, when the leech has sucked an average of 5-
10ml of blood, leech was detached by pouring a drop of 
betadine in leech bite area. Sometime leech also got detached 
itself. We allowed the blood to flow for a few minutes after 
detachment. Later on, leech bite area was cleaned with 
betadine solution and antiseptic compression bandaging was 
done. Next day, dressing was opened to check for fresh 
bleeding and patient was thereafter discharged. (Figure 1) 
 
 
1)   2)  
3)    4)  
Figure 1: Procedure of leech application 
Case presentation  
Case 1: A 35-years-old Indian female of low socio-economic 
status, admitted from Medicine OPD of Majeedia Unani 
Hospital (MUH), presented with a 10-years history of 
debilitating migraine headaches 25-26 days and 15-16 
migraine days with classic aura per month, satisfying the 
International Classification of Headache Disorders-2 (ICHD-
2) criteria. She described them as the worst feeling of her 
life, with a pain scale rating of 10 out of 10 on the VAS 
scale. The MRI showed no obvious abnormality. The total 
MSQ (migraine specific quality of life questionnaire) score in 
the first visit was 20 which showed severity in headache and 
extremely deranged quality of life in this case. Patient was 
taking Voveran (Dichlofenac sodium 75mg) injection and 
Combiflam tablet (Ibuprofen, 400mg and Parcetamol, 
325mg) around 6-8 tablets to control her symptoms. She 
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also was also taking Triptan and other NSAIDs but since 2 
years was getting no relief. 
Case 2: 29-years-old Indian female came to OPD of MUH 
female with complains of migraine, hair loss and gastritis 
from 3 years, satisfying the ICHD-2 criteria for CM. She 
typically had more than 20 days per month of headaches. She 
experienced migraine without aura, around 10 per month. 
The total MSQ score in the first visit was 30. Patient was 
taking Voveran injection and Dichlovene (Dichlofenac, 50mg 
& Paracetamol, 500mg), around 2 tablets during migraine 
and one tablet daily to ease her headache.  
Case 3: 50 years old female Indian patient admitted with a 
long history of migraines, and headaches from 10 years.  She 
had severe headaches of more than 15 days and migraine 
without aura for more than 12 days per month, diagnosed as 
CM. She occasionally required parenteral analgetic 
injectables by a local practitioner at home. She was taking 
Dichlovene (Dichlofenac, 50mg & Paracetamol, 500mg), 
around 2 tablets daily to relive such headaches. Total MSQ 
score in the first visit was 30. 
Case 4: 38 years Indian male came to the outpatient 
department of MUH with history of migraine and poly-
arthralgia, complying with the ICHD-2 criteria for CM. He 
typically experienced more than 8 migraines per month 
without classic aura, as well as mild to moderate frequent 
episodic daily headache. Patient was taking Voveran 
injection during migraine and Dichlofenac 100mg SR during 
daily headaches. Total MSQ score in the first visit was 42. 
Case 5: Another 35-years-old Indian female, admitted in 
MUH, presented with a 12-years history of migraine 
headaches 25-26 days with hair fall and insomnia. She 
typically experienced around 16-17 migraine days with 
classic aura per month, complying with the International 
Classification of Headache Disorders-2 (ICHD-2) criteria. 
Imaging of the brain showed no obvious abnormality. Total 
MSQ score in the initial visit was 20 which showed severity 
in headache and extremely deranged quality of life in this 
case. Patient was taking Voveran (Dichlofenac sodium 75mg) 
injection and Combiflam tablet (Ibuprofen, 400mg and 
Paracetamol, 325mg) around 3 tablets but was getting no 
relief.  
Case 6: 25 years old Indian female admitted in MUH, 
satisfying the ICHD-2 criteria for CM. She typically had more 
than 15 days per month of headaches. She experienced 
migraine without aura, around 8 per month. Total MSQ score 
in the first visit was 44. Patient was taking Voveran injection 
and Dichlovene (Dichlofenac, 50mg & Paracetamol, 500mg), 
around 2 tablets during migraine to alleviate her symptoms. 
Case 7: 55 years Indian male, admitted in MUH, satisfying the 
ICHD-2 criteria for CM. He typically experienced more than 
18 days headache and more than 10 days migraine without 
aura per month. Patient was taking Ibuprofen 600mg around 
2 tablets with parenteral analgesia to alleviate his symptoms. 
Total MSQ score in the first visit was 20. 
Outcome Measures 
Patients were requested to keep the detailed headache 
calendar. Results were evaluated based on reduction in the 
number of migraine days, number of daily migraine 
headache days and amount of analgesic use. Improvement in 
quality of life was assessed with migraine specific quality of 
life questionnaire (MSQ score) version 2.1. MSQ comprises of 
14 questions which addresses three dimensions (role 
function restrictive, preventive, and emotional function. Each 
of the three MSQ dimensions was scored independently. For 
each dimension, a higher score indicates a better health 
status. 
Statistical Analysis 
Statistical significance was calculated by means of a 
Wilcoxon signed rank test, using Graphpad Instat 3.10 32 for 
windows [Graphpad softwares Inc., San Diego, California, 
USA] created July 10, 2009. 
ns - Non significant, *P < 0.05 significant, **P < 0.01 very 
significant, ***P < 0.001 extremely significant. 
RESULTS 
After 2 months (4 sittings) of leech therapy extremely 
significant relief in condition of the patients was observed. 
Improvements in the following parameters were observed 
after treatment.  
Effect on number of migraine headache days: Before 
treatment, mean headache days in these patients were 
around 19.14 days/ month, which significantly reduced to 
around 5/ month days after treatment. (P≤ 0.01) [Table 1] 
 
Table 1: Effect of leech therapy in migraine headache days in chronic migraine 
Case No. Pre-Treatment Post- Treatment 
Case 1 25.5 10 
Case 2 20 7 
Case 3 15 3 
Case 4 15 0 
Case 5 25.5 10 
Case 6 15 0 
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Effect on number of migraine days: Before treatment, mean migraine days in these patients were 11.42 days/ month, which 
significantly reduced to 2.71 days/ month after treatment. (P≤ 0.01) [Table 2] 
Table 2: Effect of leech therapy migraine days in chronic migraine 
Case No. Pre-Treatment Post- Treatment 
Case 1 15.5 4.5 
Case 2 10 4 
Case 3 12 4 
Case 4 8 0 
Case 5 16.5 5.5 
Case 6 8 0 
Case 7 10 1 
 
Effect on total MSQ (migraine specific quality of life questionnaire) score: Before treatment, mean MSQ score in role function 
restrictive, preventive and emotional function dimension in these 7 patients were 14.71, 9, & 8 respectively which after 
treatment upgraded to 32, 19.85, & 16.25 respectively. (P≤ 0.01) [Table 3] 
 
Table 3: Effect of leech therapy in MSQ Score in Chronic Migraine 













Case 1 9 28 6 16 5 12 
Case 2 14 31 8 18 8 16 
Case 3 12 36 9 18 9 16 
Case 4 21 33 12 22 9 17 
Case 5 9 28 6 20 5 18 
Case 6 23 34 12 23 10 17 
Case 7 15 34 10 22 10 18 
Case 3, 4, 6 and 7 (57.14%), stopped taking NSAID’s while in the other participants, dose was significantly tapered. Patients 
(100%) met their normal sleep pattern. No adverse events were observed during and after leech therapy. 
 
DISCUSSION  
Migraine has been documented in Unani system of Medicine 
as entity “shaqeeqa” with clinical manifestation of  episodes 
of recurrent severe headaches, typically unilateral and 
throbbing, which may be associated with nausea, vomiting, 
photophobia or phonophobia. Approximately one-third of 
patients with migraine also experience ‘aura’ – transient 
neurological symptoms which are most frequently visual, but 
may involve speech and/or other senses. 20 Migraine with or 
without aura, both are three times more common in females 
than males. 21 
India is the richest source of medicinal leeches. Hence, 
leeches have been applied for various therapeutic purposes 
since decades. Secretion of the salivary glands of medicinal 
leeches contains more than 100 bioactive substances. These 
secretions include vasodilators, bacteriostatic, analgesic, 
anti-inflammatory and anticoagulants, anti-edematous, 
which eliminate microcirculatory disorders, restore the 
damaged vascular permeability of tissues and organs, 
eliminate hypoxia, reduce blood pressure, increase immune 
system activity, resolving the cause of pain and improve the 
bioenergetic status of the organism. 22 More than 20 
identified bioactive substances such as antistasin, eglins, 
guamerin, hirudin, saratin, bdellins, complement, and 
carboxypeptidase inhibitors have been identified. They have 
analgesic, anti-inflammatory, platelet inhibitory, 
anticoagulant, and thrombin regulatory functions, as well as 
extracellular matrix degradative and antimicrobial effects. 23 
U.S. Food and Drug Administration (USA-FDA) has allowed 
the sale of leeches in this country for plastic surgery, the 
general purpose and microsurgery in 2004. 22  
The present case series was performed with five females and 
two male patients of CM who were satisfying the ICHD-2R 
criteria. After 4 sittings of leech therapy at bilateral post-
auricular region, highly significant reduction in mean 
migraine headache days and migraine days per month was 
observed (Wilcoxon signed rank P≤ 0.01)  [Figure 2]. 
The reduction in mean migraine headache days and migraine 
days per month after treatment with leech therapy (P≤ 0.01), 
observed in our study might be much greater than those 
Ansari et al                                                                                                                  Journal of Drug Delivery & Therapeutics. 2019; 9(1-s):75-80 
ISSN: 2250-1177                                                                                  [79]                                                                                 CODEN (USA): JDDTAO 
reported in the treatment with botulinum toxin infiltrations 
(P = 0.250) (Bergmans et al, 2014) 24 and stromal vascular 
fraction (Bright et al, 2014) 25. Both of these case series have 
included CM cases similar to our cases. However, case series 
performed with botulinum toxin infiltration did not report 
any significant reduction in analgesic use. 24 While in our 
study, four cases (case 3, 4, 6 & 7) have completely 
discontinued their analgesic drugs. Moreover, in two phase 3 
Research Evaluating Migraine Prophylaxis Therapy 
(PREEMPT) trials which have recruited 1384 patients of CM 
and treated them with botulinum toxin for 12 weeks. Results 
of this large clinical trial reported that 70% of these patients 
had less than half of the number of headaches they had 
originally experienced. In our study, cases treated leech 
therapy reported nearly 1/4th of the headaches they 
originally had. Further, botulinum infiltration therapy is 
costly and the commonest side effects are neck pain, 
muscular weakness, and drooping of the eyelid. 26 
 
Figure 2: Effect of leech therapy on migraine headache and 
migraine days 
This is the second reported study to our knowledge, to 
examine the effect of post auricular leech therapy in chronic 
migraine. Previously, Bakhshi et al have conducted a quasi-
experimental pilot study to evaluate leech therapy in 
migraine headache but they have used 1 to 3 leeches in a 
single session unilaterally as well as they have not evaluated 
effect of leech therapy on migraine days and quality of life. 
They reported that single course of leech therapy offers 
benefits equal to propranolol 80 mg/day and amytriptyline 
50 mg/day  (P=0.00) in reducing pain in women with 
migraine headaches and its benefits persist at least for three 
months. 19 
The neurovascular theory of migraine states that excessive 
cortical excitability occurs due to hyperexcitability of 
neurons via. cutaneous allodynia in CM.27, 28 Due to this 
hyper-excitability, propagation of cortical spreading 
depression (CSD) occur in cortical cells. [4, 28, 29] CSD leads 
to hypoperfusion of cortical cells owing to vaso-constriction 
of cortical vascular bed which starts migraine and headache 
attacks evident by observations of Olsen et al and PET scan 
during migraine attacks.4 Headache may end when 
compensatory hyper-perfusion occurs which activate 
trigeminal vascular system (TVS) to stimulate the release of 
CGrP (calcitonin G related peptide) from peripheral neuronal 
terminals. The latter is the key neuropeptide in the 
mechanism of migraine and levels correlate with the degree 
of headache pain. CGrP plays an important role in the 
transmission of meningeal input to the brain 4, 26 and cause 
neurogenic inflammation of the dura matter. 30 
Conventional NSAID’s, and other anesthetic and anti-
inflammatory drugs benefits on the basis that they 
downstream propagation of  CSD 30 as well as reduced the 
plasma protein extravasation in the dura matter and 
nociceptors in peripheral arm of TVS and meninges. 32, 33 The 
observed anti-migraine effect with leech therapy could be 
due to presence of anesthetic and anti-inflammatory 
substances in leech saliva such as antistasin, hirustasin, 
ghilantens, eglin C, LDTI, complement C1 inhibitor, guamerin 
and piguamerin, carboxypeptidase inhibitor, bdellins and 
bdellastasin 23 which when enters the circulation might have 
prevented the propagation of CSD viz a viz prevented the 
hypoperfusion of cortical cells which is the culprit of 
beginning of migraine attacks. 22 Hypoperfusion and later on 
compensatory hyper-perfusion is associated with 
inflammation of the cortical cells, TVS and neural sheaths of 
neurons which lead to migraine headache. 31 Leech saliva 
contains above mentioned anti-inflammatory and 
antiedematous  substances which might have reduced the 
inflammation of cortical areas, peripheral arm of TVS as well 
as neural sheath, could be the plausible mechanism of 
reduction of migraine headaches in our patients. 22 
Conventional medicine such as Beta adrenergic blockers 
(propranolol, atenolol etc.) seems to exert therapeutic effects 
in migraine via actions at sites in the central nervous system 
(CNS) intimately involved with nociception (locus coeruleus, 
thalamus). Propranolol has a high affinity for 5-HT binding 
sites in the CNS and antagonizes serotonin (5-HT1A and 5-
HT2B receptors), thus reducing neuronal hyperexcitability 
viz prevention of propagation of CSD. 34, 35 In addition, they 
relax smooth muscles of blood vessels by blocking B-
adrenergic receptors. 35 It is well known that leech saliva 
contain substances such as acetylcholine. 23Acetylcholine 
acts as an antagonist to the 1-tryptophan, facilitating the 
catabolism of serotonin. It is equally a relaxant of endothelial 
smooth muscle.36 Thus, acetylcholine in leech saliva might 
have antagonize serotonin and reduced the hyperexcitability 
in neurons as well as acted as well as relaxed smooth 
muscles of blood vessel, similar B-blockers.  
Bakhshi et al. have proposed that the anti-inflammatory and 
analgesic substances in the leech saliva might have the 
property to reduce the release of CGRP from neurovascular 
terminals through inhibition of TVS and thus induced the 
analgesic action. Also, physical effects of leech therapy in 
reducing pain might be due to the excretion or dilution of 
numerous inflammatory mediators such as cytokines. 19 
 
Figure 3: Effect of leech therapy on dimensions of MSQ score 
Similarly in our study, our cases have experienced improved 
quality of life after leech application. Mean scores of MSQ 
dimensions (role function restrictive, preventive and 
emotional function) was upgraded. [Figure 3] For each 
dimension, a higher score indicates a better health status. So 
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observed in our study, possibly due to reduction in migraine 
& tension states, return toward normal sleep pattern, 
reduction in amount of analgesic drugs and associated 
symptoms of NSAID induced gastritis. 
CONCLUSION  
In our experience, post auricular leech therapy can 
significantly control migraine headache and migraine days 
without any adverse events. The therapy can improve the 
quality of life in chronic migraine cases. So further clinical 
trials should be conducted to substantiate absolute efficacy 
and mechanism of action of medicinal leeches by measuring 
CGRP (calcitonin G related peptide) levels in chronic 
migraine. 
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